
Biocon's Cancer Drug Jobevne Approved by U.S. FDA!
Biocon Biologics has achieved a significant milestone with the approval of its cancer-fighting antibody, Jobevne, by the U.S. Food and Drug Administration (FDA). This humanized monoclonal antibody will help treat various cancer types and adds to the company's growing portfolio in the U.S., which already includes other products like OGIVRI and FULPHILA. CEO Shreehas Tambe emphasized that this approval highlights their expertise in biotechnology and commitment to providing affordable medical solutions. Despite this major achievement, Biocon's shares dropped over 5% on the stock market, signaling mixed reactions from investors.